October is marked as Breast Cancer Awareness Month, originating from a 1985 collaboration between the American Cancer Society and AstraZeneca to promote awareness and access to services. Roche, a prominent Swiss healthcare company founded in 1896, has been a leader in cancer medications and diagnostics, achieving significant milestones in research and development, such as the licensing of the cancer drug Herceptin. The document also discusses the challenges Roche faces, including market competition and stringent regulations, while highlighting Herceptin's high cost and common side effects.

1. Go Pink, Its October…

2. October? What's Special?
• The national annual campaign began in 1985 as a partnership between the
American Cancer Society and AstraZeneca, a pharmaceutical corporation and
developer of several cancer drugs, “to promote breast cancer awareness, share
information on the disease and provide greater access to services.”
• Additionally, the third week of October has become “Male Breast Cancer
Awareness Week” since 2009 when several advocacy groups partnered to raise
awareness.

3. 2015 BC

5. The Home : Doing Now What Patients Need
Next
• Founder : Fritz Hoffmann-La Roche
• Founded : 1896
• Headquarter : Switzerland
• Revenue : 47.462 billion Swiss francs (CHF) (2014)
• Achievement : 3rd in Top 50 Global Pharmaceutical Companies
2015 (SyncForce)

6. Strength Weakness
Opportunity Threat
SWOT

7. • Over 80,00 employees present all over the world including Africa, America, Europe, Asia,
Australia
• It is one of the world’s leading supplier of cancer medicines and the number one in
vitro diagnostics company.
• Innovation through a focus on R&D on pharmaceuticals and diagnostics
• Only drug company authorized to manufacture oseltamivir(Tamiflu), a drug against
avian/swineflu.
• It is the biggest biotechnology company, with 14 biological products on the market
• Has collaborated with big pharma companies for effective operations and R&D
Strength
• Imitation of products/ fake medicines supplied under brands name can affect
brand
• Products may be available only in certain countries
Weakness

8. • Strategic agreements with other pharmaceutical companies
and organizations to boost its research.
• Increasing awareness about healthcare needs
• Global penetration through mergers and acquisitions
• Increasing demand for quality healthcare solutions
Opportunity
• Risk of unsuccessful new Products
• Regulatory environment is becoming more & more
stringent
• Economic slowdown and global financial fluctuations
Threat

9. Journey starts from…
• On October 1, 1896, at the age of 28, Fritz Hoffmann-La Roche launched
his company as the successor company to Hoffmann, Traub & Co in Basel,
Switzerland.
• He was among the first to recognise that the industrial manufacture of
medicines would be a major advance in the fight against disease.
• Since then, Roche has grown into one of the world's leading healthcare
companies.

10. The Era of Growth

11. Let’s Go Together…
• In 1980 Roche Nutley and Genentech, a biotech company based in South San Francisco, begin
a joint project to produce a genetically engineered version of a substance.
• During this period Roche found that Genentech’s scientists have discovered an unusual
mutant rat gene that produced cancer features in transfected cells and named it “neu.”
• Following work that began in the early 1980s, a Genentech team of scientists, including Axel
Ullrich and Art Levinson, clone the first full-length human HER2 gene. This achievement is
described in a paper published in Science.
• And this was the stage from where Roche started Acquiring Genentech shares in pieces.

12. Herceptin(Trastuzumab) - Ready, Steady,
Go…
• In 1992 Genentech filed an Investigational New Drug Application (IND) with
the U.S. Food and Drug Administration (FDA) and Phase I clinical trials were
initiated.
• Genentech and Roche signed a licensing agreement giving Roche exclusive
marketing rights for Herceptin outside of the United States(July 1998).
Phase Year
Preclinical Trials 1980
Phase I 1992
Phase II 1993
Phase III 1997
Post Marketing Surveillance September 1998

13. A Long way to go…
• In December 2001 Genentech received FDA approval to include, in the product
label, data that showed an improved median overall survival for women.
• In January 2008, Patients received their first dose of Herceptin and found chills
and fever as well as nausea, vomiting, pain, headache, dizziness, shortness of
breath, low blood pressure, rash, and weakness.
• After bunch of modifications in October 2010 The FDA approved Herceptin in
combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment
of patients with breast cancer.

14. Life Cycle…
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales & Sales Forecast

15. PLC Curve
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Curve

16. Herceptin in Incredible India
• The bad news is that Herceptin is probably one of the most expensive drugs in the
world, costing approximately Rs. 1,10,000 for a vial of 440 mgs.
• Depending on the weight of the patient, the normal course prescribed is around 17-
19 doses spread over a period of one year. Cumulatively that comes to around
Rs.18,00,000-Rs.20,00,000 per patient.
• Compulsory License request was filed by Biocon and Milan for production of
Trastuzumab by launching CANMab and Hertraz respectively.
• They have forecasted the sales of their form $21 million in comparison of $5.89
billion sales of Herceptin(Roche).
• Roche kicked them out of the way.(Feb 1, 2014)

17. Each one of them has it…
• Common side effects of Herceptin include:
 Diarrhoea
 Redness/irritation at injection (IV) site
 Muscle/joint/back pain
 Stomach/abdominal pain
 Headache, sleep problems (insomnia)
 Nausea and vomiting (may be severe)
 Weight loss, rash, altered sense of taste, mouth sores and loss of
appetite.

18. Reference
• http://indiancountrytodaymedianetwork.com/2015/10/19/october-breast-
cancer-awareness-month-what-do-you-need-know-162095.
• http://www.roche.com
• Images by Google

19. “Proud as we are of our past
and present achievements,
what really excites us,
however, is the future.”
Severin Schwan, CEO
Thank You